Citable filing context
SYK's research view summarizes recent SEC filing context, starting with earnings from Jul 30, 2026.
| Filed | Item | Context |
|---|---|---|
| Jul 30, 2026 | earnings | Stryker reported second quarter 2026 net sales of $6.6 billion, a 9.4% increase, and EPS of $3.30. |
| Jun 26, 2026 | acquisition | Stryker (SYK) completed the acquisition of Inari Medical Inc. |
| May 20, 2026 | management_change | William E. Berry, Jr. retires as CAO; Emily Baculik appointed Chief Accounting Officer effective September 1, 2026. |
| Jul 30, 2026 | Guidance: adjusted_net_earnings_per_diluted_share | 14.95 to 15.10 |
| Jul 30, 2026 | Guidance: organic_net_sales_growth | 8.30 to 9.30 |
| Apr 30, 2026 | Guidance: adjusted_net_earnings_per_diluted_share | 14.90 to 15.10 |
| Jul 31, 2026 | mda_quarterly | Stryker Corporation reported strong performance for the second quarter of 2026, with net sales growing 9.4% to $6.59 billion, or 9.0% in constant currency. This growth was driven by increased unit volume across all MedSurg, Neurotechnology, and Orthopaedics business units. Adjusted operating income margin expanded by 170 basis points to 27.4%, bolstered by a reduction in certain import tariffs and lower amortization of inventory stepped up to fair value. The company recently reorganized its reporting structure, creating an "Ortho Tech" segment that combines orthopaedic instruments with other orthopaedic portfolios. While Orthopaedics saw solid growth, management anticipates a potential unfavorable impact on overall gross margins in the future due to faster sales growth in the lower-margin MedSurg and Neurotechnology segment. Operational challenges included a cybersecurity incident in the first quarter of 2026, which caused idle production time and increased manufacturing costs. Despite this, the company maintains a robust liquidity position, with $3.48 billion in cash and marketable securities. Stryker continues to prioritize a capital allocation strategy focused on acquisitions, dividends, and share repurchases. The company remains exposed to ongoing risks, including regulatory compliance, product recalls, and potential volatility in effective tax rates due to global legislative changes. |
| May 11, 2026 | mda_quarterly | Stryker reported first-quarter 2026 net sales growth of 2.6%, or 1.0% in constant currency, with organic sales increasing 2.1% from higher unit volume and pricing. Adjusted operating income margin contracted 180 basis points to 21.1%, and adjusted diluted EPS decreased 8.5% to $2.60. A significant cybersecurity incident caused operational disruptions, leading to higher manufacturing and supply chain costs and idle production time, which negatively impacted gross profit margin (63.3%) and operating income across both segments. MedSurg and Neurotechnology sales grew 5.0% (3.6% constant currency), driven by strong performance in Vascular (up 27.5%) and Instruments. Orthopaedics sales were flat (down 1.8% constant currency), but organic sales increased 4.1% from higher unit volumes across Knees, Hips, and Trauma & Extremities. The company reorganized, forming a new Ortho Tech business by combining orthopaedic instruments with Mako and other enabling technologies to enhance innovation. Macroeconomic risks include new tariffs, slower economic growth, and inflation. Cash flow from operations improved significantly to $581 million. |
Source: SEC EDGAR filing text and events; period Jul 30, 2026; filed Jul 30, 2026.
SYK company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.